Search clinical trials for: BI 135585

Total 1224 results

Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid

Healthy

Netherlands
Boehringer Ingelheim

Completed

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

Psoriasis

United States, Canada, Germany
Boehringer Ingelheim

Completed

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Alzheimer Disease

Spain, United Kingdom, Italy, United States, Canada, Germany, Greece, Austria, Norway, France, Japan, Hungary, Poland, Finland
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim

Recruiting

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Bronchiectasis

Belgium, Germany, Korea, Republic of, Australia, Spain, Netherlands, Denmark, Bulgaria, Japan, Turkey, United States, Czechia, France, Hungary, Italy, Latvia, Poland, Canada, Portugal
Boehringer Ingelheim

Active, not recruiting

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Healthy | Obesity

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469

Healthy

Germany
Boehringer Ingelheim

Completed

4 Weeks Treatment of Type II Diabetic Patients With BI 44847

Diabetes Mellitus, Type 2

Germany, Netherlands
Boehringer Ingelheim

Completed

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

Lupus Nephritis

Spain, United Kingdom, United States, Canada, Thailand, Germany, Italy, Japan, Serbia, Australia, Korea, Republic of, Mexico, Malaysia, Philippines, Poland, Portugal, Greece, Hong Kong, Czechia, France
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Boehringer Ingelheim

Active, not recruiting

Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Neoplasm Metastasis

United States, United Kingdom, Canada
Boehringer Ingelheim

Recruiting

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Obesity | Overweight

China
Boehringer Ingelheim

Completed

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test Whether BI 456906 Helps Japanese People Living With Obesity Disease (SYNCHRONIZE™JP)

Obesity

Japan
Boehringer Ingelheim

Terminated

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

Psoriasis

United States, Canada, Germany
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 685509 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Terminated

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung

Netherlands
Boehringer Ingelheim

Completed

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Small Cell Lung Carcinoma | Neuroendocrine Neoplasms

United States, Belgium, Spain, Korea, Republic of, United Kingdom, Germany, Japan, China, Taiwan, France, Portugal, Bulgaria
Boehringer Ingelheim

Withdrawn

Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects

Healthy

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Patients With Small Cell Lung Carcinoma and Other Neoplasms

United States, Spain, Germany, Japan
Boehringer Ingelheim

Withdrawn

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

Asthma
Boehringer Ingelheim

Not yet recruiting

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

Healthy
Bergen University College
University of Bergen; Duke University; Haukeland University Hospital; University... and other collaborators

Active, not recruiting

Assessment and Treatment of Patients With Long-term Dizziness in Primary Care (LODIP)

Vertigo | Dizziness | Vestibular Neuritis

Norway
Boehringer Ingelheim

Completed

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Healthy

Belgium
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer

Neoplasms

Korea, Republic of, Taiwan, Japan
Boehringer Ingelheim

Withdrawn

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

COVID-19
Boehringer Ingelheim

Withdrawn

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids

Asthma
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects

Healthy Volunteers

Germany
Boehringer Ingelheim

Completed

BI 894999 First in Human Dose Finding Study in Advanced Malignancies

Neoplasms | NUT Carcinoma

United States, Spain, Belgium, Germany, France, Korea, Republic of
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 1015550 Are Taken up in the Body of Healthy Japanese Men

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body

Healthy

China
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Pancreatic Neoplasms

Austria, Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein

Healthy

Belgium
Boehringer Ingelheim

Completed

Dose Finding Study of BI 836880 in Patients With Solid Tumors

Neoplasms

Germany, France
Boehringer Ingelheim

Completed

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body

Healthy | Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body

Healthy | Chronic Kidney Disease

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Netherlands
Boehringer Ingelheim

Completed

Weekly BI 836880 in Patients With Advanced Solid Tumors

Neoplasms

Spain, France
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

Neoplasms

Hungary
Boehringer Ingelheim

Completed

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse

Leukemia, Myeloid, Acute

United States
Boehringer Ingelheim

Completed

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Wet Macular Degeneration

Austria, Germany, Hungary

3

Subscribe